Namocell, MGH Collaborate on Circulating Tumor Cell Research

Dec 16, 2016

NEW YORK (GenomeWeb) – Namocell, a developer of microfluidic-based single-cell sorting and capturing platforms, has announced a collaboration with researchers at Massachusetts General Hospital to research circulating tumor cells.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Namocell, MGH Collaborate on Circulating Tumor Cell Research

To read the full story....

Breaking News

FDA Authorizes Quest Diagnostics SARS-CoV-2/Flu Test With Self-Collection Kit for Emergency Use

Ravgen Sues Illumina, Roche Alleging Infringement of Cell-Free DNA Testing Patents

FDA Declines to Review EUA for Chembio Diagnostics SARS-CoV-2 Antibody Test

Sherlock Biosciences Licenses US Dx Rights to CRISPR-Cas12 From Tolo Biotech

FDA Authorizes Use of Pooled Samples With CDC Coronavirus Test

In Brief This Week: Agilent, Unilabs, Caris Life Sciences, and More

Featured White Papers

Case Study: Deployment of High-Throughput SARS-CoV-2 Testing at UC Davis

What's Popular?

Ravgen Sues Illumina, Roche Alleging Infringement of Cell-Free DNA Testing Patents

Illumina, New York Healthcare Providers, NYGC Partner on Clinical Whole-Genome Sequencing

Local Coverage Determinations Roundup: Castle Bio

Diaceutics, Alva10 Gathering Evidence Base for Improving PD-L1 Test Reimbursement

Breast Cancer Trial Data Supports Neoadjuvant Use of Natera Liquid Biopsy

Sponsorships